Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03563248 · ClinicalTrials.gov registry record · Phase 2
Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
A Phase 2 study of Pancreatic Cancer, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 168
- Enrollment target
- 10
- Study locations
NCT03563248: Active Phase 2 study of Pancreatic Cancer, sponsored by Massachusetts General Hospital.
NCT03563248 is a Phase 2 study of Pancreatic Cancer that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 168 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (57% lower). The trial reports 10 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03563248, a Phase 2 study of Pancreatic Cancer, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 168 participants
- Enrollment target
- 10
- Study locations
Study Summary
This research study is studying a combination of interventions as a possible treatment for pancreatic tumor. The interventions involved in this study are: * FOLFIRINOX which is made up of 4 different drugs: * 5-Fluorouracil (5-FU) * Oxaliplatin * Irinotecan * Leucovorin * Losartan * Nivolumab * Radiation Therapy * Surgery
Primary Outcome
R0 resection is defined as microscopically negative margins determined by histopathologic assessment of the resection specimen. The R0 resection rate will be analyzed among all eligible patients, including those not resected due to early progression, death or off-study.
Conditions Studied
Interventions
- DRUG Nivolumab
- PROCEDURE Surgery
- DRUG Losartan
- RADIATION SBRT
- DRUG FOLFIRINOX
Study Locations (10)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
- Newton Wellesley Hospital - Newton
Colorado
- University of Colorado Cancer Center - Aurora
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Maryland
- The Johns Hopkins Hospital - Baltimore
New York
- New York University Langone Medical Center - New York
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2018-08-10 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
What the registry record for NCT03563248 still lists
NCT03563248 is an interventional study that assigns participants to a tested intervention. The registered 168 participants enrollment target is mid-sized for trials with a published cap, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 5 interventions - of which Nivolumab is the first listed.
NCT03563248 lists 10 locations in 6 states (Massachusetts, Colorado, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT03563248 about?
NCT03563248 is a clinical study titled "Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer". This research study is studying a combination of interventions as a possible treatment for pancreatic tumor. The interventions involved in this study are: * FOLFIRINOX which is made up of 4 different drugs: * 5-Fluorouracil (5-FU) * Oxaliplatin * Irinotecan * Leucovorin * Losartan * Nivol...
What is the current status of trial NCT03563248?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2018-08-10. Estimated completion is 2027-04.
What conditions does trial NCT03563248 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT03563248?
The interventions under investigation include: Nivolumab (DRUG), Surgery (PROCEDURE), Losartan (DRUG), SBRT (RADIATION), FOLFIRINOX (DRUG).
Who is sponsoring clinical trial NCT03563248?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03563248 being conducted?
This trial has 10 study locations across Colorado, District of Columbia, Maryland, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03563248's enrollment target sits among peer trials
168 74th of 278 higher than 205 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02118922 · 168 participants
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
- NCT03536897 · 168 participants
IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry
- NCT04078230 · 168 participants · NA
Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma
- NCT04159168 · 168 participants · NA
Facial Affect Sensitivity Training for Young Children With Callous-unemotional Traits
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI